CS1001
AssetAlso WBP-315, Sugemalimab, Cejemly
Anti-PD-L1 monoclonal antibody blocking immune checkpoint inhibition.
- Stage
- Phase 3
- Modality
- Antibody
- Target
- CD274
- 2
- Indications
- 2,008
- Trials
- 1
- Developer
Indications
2Unresectable locally advanced recurrent or metastatic esophageal squamous cell carcinoma
Phase 3, Completed, NCT04187352, clinicaltrials.gov, 7 Oct 2026
Advanced solid tumor
Phase 1, Recruiting, NCT06741644, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials2,008
- Evidence for its targets2
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.